MedPath

Online Low-FODMAP Diet in Irritable Bowel Syndrome

Not Applicable
Completed
Conditions
Irritable Bowel Syndrome
Registration Number
NCT07172581
Lead Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Brief Summary

This study aimed to assess the impact of implementing the low Fermentable Oligo-, Di- and Monosaccharides, And Polyols (FODMAP) diet, through an online educational service platform, on the quality of life of patients living with irritable bowel syndrome (IBS). A prospective single-group intervention pilot study involving patients with IBS from two hospitals was conducted. Participants followed the low FODMAP diet using a web-based platform for 6 months. The IBS quality of life questionnaire (IBS-QoL), the IBS symptom severity scoring system (IBS-SSS) and the State-Trait Anxiety Inventory Form Y (STAI) were completed at baseline, after the restriction phase and after reintroduction of tolerated FODMAPs.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • have a diagnosis of IBS according to the Rome IV criteria by a gastroenterologist within the past three months
  • understand French
  • have an Internet access and a Facebook© account with a self-reported familiarity to use them
Exclusion Criteria
  • patients suffering from a known eating or mental health disorder
  • body mass index under 18.5 kg/m2
  • type 1 or 2 diabetes
  • pregnancy
  • other chronic gastrointestinal diseases, except gastroesophageal reflux

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
IBS-related quality of lifeFrom enrollment to the end of intervention at 6 months.

The primary outcome was the change in QoL from baseline to the end of study, assessed by the validated IBS-QoL questionnaire. This questionnaire assesses 8 domains, namely dysphoria, interference with activity, body image, health worry, food avoidance, social reaction, sexual concerns and relationships, from which a computed score is drawn. This score, ranging from 0 to 100, was developed to assess the self-reported QoL in IBS, a higher score indicating a better QoL.

Secondary Outcome Measures
NameTimeMethod
Severity of IBS symptomsFrom enrollment to the end of intervention at 6 months.

Secondary outcomes included changes in severity of IBS symptoms, measured by the validated IBS-Severity Scoring System (IBS-SSS) (Francis et al., 1997). This questionnaire evaluates 5 specific domains within the last ten days: abdominal pain severity, abdominal pain duration, abdominal distension, bowel habits dissatisfaction and interference with life. A composite score is calculated and varies from 0 to 500. Depending on the score, the severity can be classified in 4 categories: absence of symptoms severity or remission (score \< 75), mild (score 75-174), moderate (score 175-299), and severe (score ≥ 300).

State and trait anxietyFrom enrollement to the end of intervention at 6 months.

Anxiety was evaluated by the French-Canadian adaptation of the State-Trait Anxiety Inventory Form Y (STAI) (Gauthier and Bouchard, 1993; Spielberger, 1983), which specifically assesses state anxiety (STAI-S), the subjective and transient emotional state of anxiety, and trait anxiety (STAI-T), a more stable predisposition to anxiety. The STAI-S score can be classified in 5 categories: very low state anxiety (score \< 36), low (score 36-45), moderate (score 46-55), high (score 56-65), and very high (score \> 65) (Bauer et al., 2016). For the STAI-T score, a score inferior to 40 commonly indicates low trait anxiety while a score of 40 or more indicates high trait anxiety (Kose et al., 2021).

Trial Locations

Locations (1)

Centre de recherche du Centre Hospitalier de l'Université de Montréal

🇨🇦

Montreal, Quebec, Canada

Centre de recherche du Centre Hospitalier de l'Université de Montréal
🇨🇦Montreal, Quebec, Canada

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.